Incorporation of brentuximab vedotin into first-line treatment of advanced classical Hodgkin's lymphoma: final analysis of a phase 2 randomised trial by the German Hodgkin Study Group

著者: Dennis A. Eichenauer, Annette Plütschow, Stefanie Kreissl, Martin Sökler, Johannes C. Hellmuth, Julia Meißner, Stephan Mathas, Max S. Topp, Karolin Behringer, Wolfgang Hiddemann, Georg Kuhnert, Markus Dietlein, Carsten Kobe, Michael Fuchs, Volker Diehl, Andreas Engert, Peter Borchmann - The Lancet 2017 被引用: 113